Back
Compare AU
Compare ZYAU vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P/ASX 200 High Dividend ETF (ZYAU) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ZYAU | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 105 | 81 |
Median incremental investment | $701.07 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,956.21 | $2,342.98 |
Average age group | > 35 | > 35 |
Key Summary
ZYAU | CURE | |
|---|---|---|
Strategy | ZYAU.AX was created on 2015-06-09 by Global X. The fund's investment portfolio concentrates primarily on high dividend yield equity. The Global X S&P/ASX 200 High Dividend ETF (ZYAU.AX) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P/ASX 200 High Dividend Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ANZ Group Holdings Ltd (10.73 %) National Australia Bank Ltd (9.94 %) Westpac Banking Corp (9.61 %) | Twist Bioscience Corp (2.20 %) Moderna Inc (2.04 %) Natera Inc (1.81 %) |
Top 3 industries | Financials (48.63 %) Materials (21.07 %) Other (11.25 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (98.22 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) New Zealand (0.62 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.24 % | 0.45 % |
Key Summary
ZYAU | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | S&P/ASX 200 High Dividend Index - AUD - Benchmark TR Gross | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.24 % | 0.45 % |
Price | $9.93 | $76.53 |
Size | $100.270 million | $49.412 million |
10Y return | -6.85 % | N/A |
Annual distribution yield (5Y) | 5.39 % | 0.03 % |
Market | ASX | ASX |
First listed date | 12/06/2015 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ZYAU | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 105 | 81 |
Median incremental investment | $701.07 | $678.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,956.21 | $2,342.98 |
Average age group | > 35 | > 35 |
Pros and Cons
ZYAU | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ZYAU | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |